secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001641172-25-008682
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma appoints Michael Breen as CEO, effective April 29, 2025
--------------------------------------------------------------------

- Michael Breen appointed CEO for a two-year term; he had served as Interim CEO since March 2022.
- Breen continues as Executive Chairman and Board member, roles held since January and November 2021.
- Breen is a UK-qualified solicitor and former senior partner at Clyde & Co., advising biotech clients.
- No compensatory terms or changes to existing arrangements disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/0001641172-25-008682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-008682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer